Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Authors:
- Mykola KhalangotMKMykola Khalangot
- Mykola TronkoMTMykola Tronko
- Victor KravchenkoVKVictor Kravchenko
- Vladimir KovtunVKVladimir Kovtun
- 1 December 2009
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 86 (3) , 247-253
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Current practice of insulin and oral hypoglycaemic agents treatment of diabetes mellitus type 2 patients according to diabetes mellitus register data analysis in the city of Donetsk, UkrainePrimary Care Diabetes, 2007
- Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortalityDiabetes/Metabolism Research and Reviews, 2007
- A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular EventsDiabetes Care, 2007
- The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitusBritish Journal of Clinical Pharmacology, 2006
- Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic DrugsAmerican Journal of Therapeutics, 2006
- GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patientsEuropean Journal of Clinical Investigation, 2004
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with GlibenclamideHormone and Metabolic Research, 1996
- Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patientsThe American Journal of Medicine, 1991
- Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: Structural requirements and cellular mechanismsEuropean Journal of Pharmacology, 1987